Archives of the Turkish Society of Cardiology

Volume: 45 Suppl: 4 - September 2017

EDITORIAL
1.	Editorial Murat Özdemir PMID: 28947722 Page III DOWNLOAD

INVITED REVIEW
2.	EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism Cihangir Kaymaz PMID: 28947723 doi: 10.5543/tkda.2017.02646 Pages 1 - 7 Abstract \|Full Text PDF

3.	After the GEMINI-ACS-1 trial Mehmet Birhan Yılmaz PMID: 28947724 doi: 10.5543/tkda.2017.52358 Pages 8 - 9 Abstract \|Full Text PDF

4.	PIONEER AF-PCI trial Murat Özdemir PMID: 28947725 doi: 10.5543/tkda.2017.04524 Pages 10 - 14 Abstract \|Full Text PDF

5.	Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials Rabia Akıllı, Mesut Demir PMID: 28947726 doi: 10.5543/tkda.2017.27632 Pages 15 - 23 Abstract \|Full Text PDF

6.	Importance of adherence and persistence in anticoagulant treatment: Advantages of once daily dosing Erdem Diker PMID: 28947727 doi: 10.5543/tkda.2017.03446 Pages 24 - 25 Abstract \|Full Text PDF

7.	How should one read “real-life data” regarding NOAC’s? “The case with rivaroxaban” Özgür Aslan PMID: 28947728 doi: 10.5543/tkda.2017.33903 Pages 26 - 32 Abstract \|Full Text PDF